Policy Developments - The National Medical Products Administration (NMPA) is optimizing the review and approval process for urgently needed overseas drugs that have already been marketed, aiming to meet the pressing clinical needs of patients [1] Drug and Device Approvals - Yifan Pharmaceutical's subsidiary received a registration acceptance notice for Yihuang Decoction Granules, which is indicated for kidney strengthening and dampness clearing [2] - Zhenghai Bio announced that it received a medical device registration acceptance notice for a uterine cavity repair membrane, currently in the acceptance stage [3] - Microchip Biotech's Xidabendan Tablets have been approved for sale in Macau, marking an expansion into overseas markets [4] - Heng Rui Medicine's innovative drug Ruirafulpu α injection has been approved for marketing, with no similar products currently approved domestically or internationally, and a cumulative R&D investment of approximately 711 million yuan [5] Capital Market Insights - Bibet reported that it is not yet profitable and has accumulated unremedied losses, with only one product approved and several others in various clinical trial stages, indicating a need for significant ongoing R&D investment [6] - Innovation Medical confirmed that its production and operational status is normal, with no undisclosed significant matters [7][8] Industry Events - Yiming Onco announced the termination of its collaboration agreement with Axion Bio, regaining global development and commercialization rights for two core anti-cancer drugs, with previously received payments unaffected [9] Public Opinion Alerts - The Director of the Jiangxi Provincial Health Commission is under disciplinary review and investigation for serious violations of discipline and law [10]

Core Viewpoint - The collaboration between Yiming Oncology and Axion Bio has been terminated due to slow clinical progress by Axion, leading Yiming to regain global rights for two key cancer drugs, IMM2510 and IMM27M, while retaining the previously received $35 million in upfront and milestone payments [2][4]. Group 1: Collaboration Termination - Yiming Oncology announced the termination of its licensing agreement with Axion Bio on January 6, regaining global development and commercialization rights for IMM2510 and IMM27M [2]. - The partnership began in August 2024, with Yiming granting Axion exclusive rights outside Greater China, and Yiming receiving a total of $20 million in upfront and recent payments [2][7]. - The abrupt end of the collaboration was attributed to Axion's slow overseas clinical advancement, as stated by a Yiming representative [2]. Group 2: Financial Implications - Yiming has secured $35 million in non-recurring income, which provides a buffer for cash flow and reinvestment, although future funding needs for global multi-center trials remain a concern [2][9]. - The termination may enhance Yiming's autonomy in clinical and commercial strategies, allowing for accelerated progress based on positive signals from Greater China [2][9]. Group 3: Industry Context - The case highlights the critical constraints of milestone fulfillment and clinical advancement in overseas collaborations, with buyers emphasizing verifiable clinical delivery and clear exit mechanisms [3]. - The termination reflects broader industry challenges, as trust between Chinese innovative drug companies and international partners is being tested, potentially leading to a trend of "returning" or "recalling" collaborations [9][11]. - The surge in business development (BD) transactions from Chinese innovative drug companies, totaling $135.655 billion in 2025, indicates a shift in collaboration models, moving towards more diversified partnerships rather than simple licensing agreements [9][10].

Core Viewpoint - Yiming Oncology has terminated its licensing agreement with Axion Bio, Inc., regaining global development and commercialization rights for two core anti-cancer drugs, IMM2510 and IMM27M, while retaining the previously received $35 million upfront and milestone payments [1] Group 1 - Yiming Oncology announced the termination of the licensing agreement with Axion Bio, Inc. [1] - The agreement was initially established on August 1, 2024, granting Axion exclusive rights for the development and commercialization of IMM2510 and IMM27M outside Greater China [1] - Following the termination, all global rights for the drugs revert to Yiming Oncology, with Axion receiving limited rights to gradually conclude its related clinical development activities [1]

Core Viewpoint - Yiming Oncology (01541) has terminated its licensing agreement with Axion Bio, Inc., regaining global development and commercialization rights for two core anti-cancer drugs, IMM2510 and IMM27M, while retaining the previously received $35 million upfront and milestone payments [1] Group 1: Agreement Termination - The collaboration with Axion was initially established on August 1, 2024, granting Axion exclusive rights for the development and commercialization of IMM2510 and IMM27M outside Greater China [1] - The termination agreement allows Axion limited rights to gradually conclude its related clinical development activities [1] Group 2: Drug Details - IMM2510 is a bispecific molecule targeting VEGF/PD-L1, utilizing mAb-Trap structure to inhibit tumor angiogenesis and activate immune cells, creating an anti-tumor synergistic effect [1] - IMM27M is a next-generation CTLA-4 monoclonal antibody with enhanced ADCC activity, capable of eliminating immunosuppressive regulatory T cells in the tumor microenvironment, thereby strengthening T cell anti-tumor responses [1] Group 3: Future Development - Yiming Oncology expresses confidence in the therapeutic potential of both drugs and plans to accelerate their clinical development process [1]